Skip to main content

MODIFICACION FARMACOLOGICA DEL REMODELADO Y EPOC INDUCIDOS POR EL HUMO DEL TABACO: VISION EN MODELOS ANIMALES Y HUMANOS.

SAF2011-26443

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2011
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre FUNDACION HOSPITAL GENERAL UNIVERSITARIO (COMUNIDAD DE VALENCIA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Anti-Inflammatory and Anti-Fibrotic Profile of Fish Oil Emulsions Used in Parenteral Nutrition-Associated Liver Disease

  • Pastor-Clérigues, Alfonso
  • Martí-Bonmatí, Ezequiel
  • Milara, Javier
  • Cortijo, Julio
  • Almudéver-Folch, Patricia|||0000-0003-3138-0862
[EN] Home parenteral nutrition (PN) is associated with many complications including severe hepatobiliary dysfunction. Commercial omega-6 fatty acid-soybean based-lipid emulsions in PN may mediate long term PN associate liver disease (PNALD) whereas omega-3-fish oil parenteral emulsions have shown to reverse PNALD in children. However, its clinical effectiveness in adults has been scarcely reported. In this work, we study the role of soybean and fish oil lipid commercial emulsions on inflammatory and profibrotic liver markers in adults with long term PNALD and in in vitro cellular models. Inflammatory and profibrotic markers were measured in serum of ten adults with long term PNALD and in culture supernatants of monocytes. Liver epithelial to mesenchymal transition (EMT) was induced by transforming growth factor beta 1 (TGF beta 1) to evaluate in vitro liver fibrosis. Omegaven (R), a 100% fish oil commercial emulsion, was infused during four months in two patients with severe long term PNALD reversing, at the first month, the inflammatory, profibrotic and clinical parameters of PNALD. The effect was maintained during the treatment course but impaired when conventional lipid emulsions were reintroduced. The other patients under chronic soybean oil-based PN showed elevated inflammatory and profibrotic parameters. In vitro human monocytes stimulated with lipopolysaccharide induced a strong inflammatory response that was suppressed by Omegaven (R), but increased by soybean emulsions. In other experiments, TGFb1 induced EMT that was suppressed by Omegaven (R) and enhanced by soybean oil lipid emulsions. Omegaven (R) improves clinical, anti-inflammatory and anti-fibrotic parameters in adults with long-term home PNALD., This work was supported by grants from "proyecots de investigacion fundamental no orientada (SAF) 2011-26443 (JC)'', "fondo de investigaciones sanitarias (FIS) CP11/00293(JM)'', "centro de investigacion biomedica en red de enfermedades respiratorias (CIBERES) CB06/06/0027'', Spanish Government ADE10/00020 (JC), as well as research grants from Regional Government Prometeo II/2013/014 (JC, JM) "Generalitat Valenciana.'' Support from the "centro para el desarrollo tecnologico e industrial (CENIT)'' programme (Spanish Government) was obtained. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease

  • Milara, Javier
  • Lluch, Javier
  • Freire, Jose
  • Xiaozhong, Qian
  • Cortijo, Julio
  • Almudéver-Folch, Patricia|||0000-0003-3138-0862
[EN] Background: Glucocorticoid functions are markedly impaired in patients with chronic obstructive pulmonary disease (COPD). The phosphodiesterase 4 inhibitor roflumilast N-oxide (RNO) is the active metabolite of roflumilast approved as a treatment to reduce the risk of exacerbations in patients with severe COPD. Objective: We sought to characterize the differential effects of RNO versus corticosteroids and their potential additive/synergistic effect in neutrophils from patients with COPD, thus providing scientific rationale for the combination of roflumilast with corticosteroids in the clinic. Methods: Peripheral blood neutrophils were isolated from patients with COPD (n = 32), smokers (n = 7), and healthy nonsmokers (n = 25). Levels of IL-8, matrix metallopeptidase 9 (MMP-9), and biomarkers of glucocorticoid resistance were determined by using ELISA and RT-PCR. Neutrophils were incubated with dexamethasone (0.1 nmol/L to 1 mu mol/L), RNO (0.1 nmol/L to 1 mu mol/L), or the combination of 1nmol/L RNO plus 10 nmol/L DEX and stimulated with LPS (1 mu g/mL) or cigarette smoke extract 5%; levels of IL-8, MMP-9, and other biomarkers were measured at the end of the incubation period. Results: Peripheral neutrophils from patients with COPD showed a primed phenotype with an increased basal release of IL-8 and MMP-9 and expressed a corticosteroid resistance molecular profile characterized by an increase in phosphoinositide 3-kinase delta, macrophage migration inhibitory factor, and glucocorticoid receptor beta expression and a decrease in HDAC activity and mitogen-activated protein kinase phosphatase 1 expression. RNO demonstrated robust anti-inflammatory effects on neutrophils from patients with COPD, reversing their resistance to corticosteroids. The combination of RNO and dexamethasone showed additive/synergistic effects, which were consistent with the reversal of corticosteroid-resistant molecular markers by RNO. Conclusion: RNO reverses corticosteroid resistance and shows strong anti-inflammatory effects alone or in combination with corticosteroids on neutrophils from patients with COPD., Supported by grants SAF2011-26443 (to J.C.), FIS CP11/00293 (to J.M.), CIBERES (CB06/06/0027), ADE10/00020 (Spanish government), and research grants from the Regional Government (Prometeo II/2013/014 to J.C. and J.M.), "Generalitat Valenciana.'' Support from the CENIT programme (Spanish Government) was obtained as well.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Phosphatidylcholine liposomes as carriers to improve topical ascorbic acid treatment of skin disorders

  • Serrano, Gabriel
  • Serrano, Juan-Manuel
  • Milara, Javier
  • Torrens, Ana
  • Expósito, Inmaculada
  • Cortijo, Julio
  • Almudéver-Folch, Patricia|||0000-0003-3138-0862
[EN] Liposomes have been intensively investigated as carriers for different applications in dermatology and cosmetics. Ascorbic acid has potent antioxidant and anti-inflammatory properties preventing photodamage of keratinocytes; however, due to its instability and low skin penetration, an appropriate carrier is mandatory to obtain desirable efficacy. The present work investigates the ability of a specific ascorbate phosphatidylcholine (PC) liposome to overcome the barrier of the stratum corneum and deliver the active agent into the dermis to prevent photodamage. Abdominal skin from ten patients was used. Penetration of PC liposomes was tested ex vivo in whole skin, epidermis, and dermis by means of fluorescein and sodium ascorbate. Histology and Franz diffusion cells were used to monitor the percutaneous absorption. Ultraviolet (UV)-high performance liquid chromatography was used to analyze diffusion of sodium ascorbate through the different skin layers, while spectrofluorimetry and fluorescent microscopy were used for fluorescein monitoring. UVA/UVB irradiation of whole skin was applied to analyze the antioxidant capacity by Trolox assay and anti-inflammatory effects by tumor necrosis factor alpha and interleukin 1 beta enzyme-linked immunoassay. PC liposomal formulation improved skin penetration of fluorescein and ascorbate. Fluorescein PC liposomes showed better diffusion through epidermis than dermis while ascorbate liposomes showed better diffusion through the dermis than the epidermis. Ascorbate PC liposomes showed preventive antioxidant and anti-inflammatory properties on whole human skin irradiated with UVA/UVB. In summary, ascorbate PC liposomes penetrate through the epidermis and allow nonstable hydrophilic active ingredients reach epidermis and dermis preventing skin photodamage., This work was supported by grants SAF2011-26443 (JC), FIS CP11/00293 (JM), FIS PI14/01733 (JM), CIBERES (CB06/06/0027), ADE10/00020 (Spanish Government), as well as research grants from Regional Government Prometeo II/2013/014 (JC, JM) "Generalitat Valenciana". Sesderma laboratories partially support this work.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Bafetinib inhibits functional responses of human eosinophils in vitro

  • Milara, Javier
  • Martínez -Losa, Maleles
  • Sanz, Celia
  • Peiró, Teresa
  • Serrano, Adela
  • Morcillo, Esteban Jesus
  • Zaragozá, Cristóbal
  • Cortijo, Julio
  • Almudéver-Folch, Patricia|||0000-0003-3138-0862
[EN] Eosinophils play a prominent role in the process of allergic inflammation. Non-receptor associated Lyn tyrosine kinases generate key initial signals in eosinophils. Bafetinib, a specific Abl/Lyn tyrosine kinase inhibitor has shown a potent antiproliferative activity in leukemic cells, but its effects on eosinophils have not been reported. Therefore, we studied the effects of bafetinib on functional and mechanistic responses of isolated human eosinophils. Bafetinib was more potent than non-specific tyrosin kinase comparators genistein and tyrphostin inhibiting superoxide anion triggered by N-formyl-Met-Leu-Phe (fMLF; 100 nM) (-log IC50=7.25 +/- 0.04 M; 6.1 +/- 0.04 M; and 6.55 +/- 0.03 M, respectively). Bafetinib, genistein and tyrphostin did not modify the [Ca2+](i); responses to tMLF. Bafetinib inhibited the release of EPO induced by tMLF with higher potency than genistein and tyrphostin (-log IC50=7.24 +/- 0.09 M; 5.36 +/- 0.28 M; and 5.37 +/- 0.19 M, respectively), and nearly suppressed LTC4, ECP and chemotaxis. Bafetinib, genistein and tyrphostin did not change constitutive apoptosis. However bafetinib inhibited the ability of granulocyte-monocyte colony-stimulating factor to prevent apoptosis. The activation of Lyn tyrosine kinase, p-ERK1/2 and p-38 induced by tMLF was suppressed by bafetinib and attenuated by genistein and tyrphostin. In conclusion, bafetinib inhibits oxidative burst and generation of inflammatory mediators, and reverses the eosinophil survival. Therefore, future anti-allergic therapies based on bafetinib, could help to suppress excessive inflammatory response of eosinophils at inflammatory sites., This work was supported by grants SAF2011-26443 (JC), SAF2012-31042 (EM), FIS CP11/00293(JM), CIBERES (CB06/06/0027), ADE10/00020 and research grants from Regional Government (Prometeo/2008/045, 'Generalitat Valenciana'. TP received a research grant from Conselleria de Educacion, Generalitat Valenciana ACIF/2010/114. Support from the CENIT programme (Spanish Government) was obtained.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Role of tetrahydrobiopterin in pulmonary vascular remodeling associated with pulmonary fibrosis

  • Almudéver-Folch, Patricia|||0000-0003-3138-0862
  • Milara, Javier
  • De Diego, Alfredo
  • Serrano-Mollar, Ana
  • Xaubet, Antoni
  • Perez-Vizcaino, Francisco
  • Cogolludo, Angel
  • Cortijo, Julio
[EN] Background Pulmonary hypertension in idiopathic pulmonary fibrosis (IPF) is indicative of a poor prognosis. Recent evidence suggests that tetrahydrobiopterin (BH4), the cofactor of nitric oxide synthase (NOS), is involved in pulmonary hypertension and that pulmonary artery endothelial-to-mesenchymal transition (EnMT) may contribute to pulmonary fibrosis. However, the role of BH4 in pulmonary remodelling secondary to pulmonary fibrosis is unknown. This study examined the BH4 system in plasma and pulmonary arteries from patients with IPF as well as the antiremodelling and antifibrotic effects of the BH4 precursor sepiapterin in rat bleomycin-induced pulmonary fibrosis and in vitro EnMT models. Methods BH4 and nitrotyrosine were measured by high-performance liquid chromatography and ELISA, respectively. Expression of sepiapterin reductase (SPR), GTP cyclohydrolase 1 (GCH-1), endothelial NOS (eNOS) and inducible NOS (iNOS) were measured by quantitative PCR and immunohistochemistry. Results BH4 plasma levels were downregulated in patients with IPF compared with controls while nitrites, nitrates and nitrotyrosine were upregulated. GCH-1 and eNOS were absent in pulmonary arteries of patients with IPF; however, iNOS expression increased while SPR expression was unchanged. In rats, oral sepiapterin (10 mg/kg twice daily) attenuated bleomycin-induced pulmonary fibrosis, mortality, vascular remodelling and pulmonary hypertension by increasing rat plasma BH4, decreasing plasma nitrotyrosine and increasing vascular eNOS and GCH-1 expression. Both transforming growth factor beta 1 and endothelin-1 induced EnMT by decreasing BH4 and eNOS expression. In vitro administration of sepiapterin increased endothelial BH4 and inhibited EnMT in human pulmonary artery endothelial cells. Conclusions Targeting the BH4 synthesis 'salvage pathway' with sepiapterin may be a new therapeutic strategy to attenuate pulmonary hypertension in IPF., This work was supported by the Spanish government by grants SAF2011-26443 (to JC), FIS CP11/00293 (to JM), CIBERES (CB06/06/0027), ADE10/00020 (to JC), FIS09/00672 (to AX), SAF2010-22066-C02-02 (to AC), research grant from the Valencia Pneumology Foundation 2010 (to AD) and support from the CENIT programme, and research grants from Regional Government (Prometeo/2008/045, 'Generalitat Valenciana').